Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113766 | 0.86 | ALDH1A1 (0.42) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL30953729 | 0.86 | FLT4 (0.37) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL30843159 | 0.86 | POLB (0.37) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL30953805 | 0.85 | NNMT (0.39) | POLBTDP1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL10558900 | 0.85 | ALDH1A1 (0.41) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL18113749 | 0.83 | L3MBTL1 (0.40) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL30953680 | 0.83 | ALDH1A1 (0.42) | POLBTDP1CA1CA2CA12 | |
| SCHEMBL24936190 | 0.82 | PDPK1 (0.38) | POLBTDP1CA9FLT4KDR | |
| SCHEMBL16583329 | 0.80 | POLB (0.49) | POLBTDP1CA1CA2FLT4 | |
| SCHEMBL18113729 | 0.80 | PDPK1 (0.37) | POLBTDP1FLT4KDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028502-B | Preparation method of kinase inhibitor drug intermediate | 济南周行医药科技有限公司 | 2020-02-14 | — | — | CN | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-117510401-B | Synthesis method of nitrogen heterocyclic iodo-compound | 渤海大学 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024083237-A1 | SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2024-04-25 | — | — | WO | disclosed |
| CN-117659001-A | Aminopyrimidine derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117510401-A | Synthesis method of nitrogen heterocyclic iodo-compound | 渤海大学 | 2024-02-06 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2017193063-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016045591-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-31 | — | — | WO | disclosed |
| US-5776858-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0771797-A1 | 1-Azinyl-tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | POLB 4563/4885TDP1 3145/4885CA1 2734/4885 |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | POLB 3033/4885TDP1 1415/4885CA1 2581/4885 |
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | POLB 3499/4885TDP1 1719/4885CA1 2192/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | POLB 1764/4885TDP1 2489/4885CA1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.